Loading video...

Video Failed to Load

Go Home

Plus Therapeutics $PSTV is a biotechnology company focused on developing innovative, targeted treatments and cutting-edge diagnostics for adults and children with difficult-to-treat cancer. They are advancing key programs, including the diagnostic platform CNSide and the targeted radiotherapeutic REYOBIQ™. Katie Perry sat down with President & CEO Dr. Marc Hedrick...

Stocktwits's profile picture

Stocktwits

1,135,776 subscribers

13,355 views • 8 months ago •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Pineapple Financial Inc. $PAPL is a mortgage tech company providing cloud-based and AI-driven tools for agents, brokers, and consumers. The company launched a $100 million digital asset treasury strategy and became the first publicly traded company to hold $INJ, pushing mortgage finance onchain with Injective. Katie Perry sat down with CEO Shubha Dasgupta to discuss how Pineapple PAPL is transforming the mortgage industry through technology, innovation, and its move into digital assets.
9:09

Pineapple Financial Inc. $PAPL is a mortgage tech company providing cloud-based and AI-driven tools for agents, brokers, and consumers. The company launched a $100 million digital asset treasury strategy and became the first publicly traded company to hold $INJ, pushing mortgage finance onchain with Injective. Katie Perry sat down with CEO Shubha Dasgupta to discuss how Pineapple PAPL is transforming the mortgage industry through technology, innovation, and its move into digital assets.

Stocktwits

1,525,264 views • 8 months ago

ProShares is an innovative leader in the ETF landscape, offering one of the largest lineups of ETFs across various strategies. Katie Perry sat down with Simeon Hyman, Global Investment Strategist at ProShares, to discuss their innovative approach to equity income using the ProShares Nasdaq-100 High Income ETF ($IQQQ).
9:28

ProShares is an innovative leader in the ETF landscape, offering one of the largest lineups of ETFs across various strategies. Katie Perry sat down with Simeon Hyman, Global Investment Strategist at ProShares, to discuss their innovative approach to equity income using the ProShares Nasdaq-100 High Income ETF ($IQQQ).

Stocktwits

1,034,359 views • 8 months ago

Aduro Clean Technologies Inc. ($ADUR) is dedicated to advancing chemical recycling beyond pyrolysis through the development and commercialization of its patented Hydrochemolytic Technology (HCT). Katie Perry sat down with CEO Ofer Vicus to discuss how Aduro Clean Technologies is powering sustainable transitions using its patented water-based technologies to chemically recycle waste plastics and their structured scale-up program.
16:00

Aduro Clean Technologies Inc. ($ADUR) is dedicated to advancing chemical recycling beyond pyrolysis through the development and commercialization of its patented Hydrochemolytic Technology (HCT). Katie Perry sat down with CEO Ofer Vicus to discuss how Aduro Clean Technologies is powering sustainable transitions using its patented water-based technologies to chemically recycle waste plastics and their structured scale-up program.

Stocktwits

1,022,881 views • 7 months ago

Surf Air Mobility $SRFM is redefining regional aviation, scaling its air mobility platform and advancing both AI-enabled software solutions powered by Palantir and future electrified aircraft At Stocktoberfest, Katie Perry sat down with Co-founder Sudhin Shahani to discuss how Surf Air Mobility is building its regional air mobility platform that blends hardware, software, and innovation to make flight more efficient and accessible
8:06

Surf Air Mobility $SRFM is redefining regional aviation, scaling its air mobility platform and advancing both AI-enabled software solutions powered by Palantir and future electrified aircraft At Stocktoberfest, Katie Perry sat down with Co-founder Sudhin Shahani to discuss how Surf Air Mobility is building its regional air mobility platform that blends hardware, software, and innovation to make flight more efficient and accessible

Stocktwits

17,861 views • 9 months ago

ETFs continue to give retail investors some of the best opportunities for market exposure and GraniteShares is helping lead the way, recently surpassing $12 billion in assets under management, a new all-time high for the firm! Katie Perry sat down with CEO Will Rhind at Stocktoberfest to discuss the milestone and what’s next for GraniteShares
13:13

ETFs continue to give retail investors some of the best opportunities for market exposure and GraniteShares is helping lead the way, recently surpassing $12 billion in assets under management, a new all-time high for the firm! Katie Perry sat down with CEO Will Rhind at Stocktoberfest to discuss the milestone and what’s next for GraniteShares

Stocktwits

5,654,092 views • 9 months ago

POET Technologies is reshaping how light and data work together with its Optical Interposer platform, making AI, data centers, and quantum computing faster and more efficient. Katie Perry sat down with CRO Raju Kankipati to discuss how POET Technologies is scaling its business, driving innovation in photonics, and powering the future of AI.
12:23

POET Technologies is reshaping how light and data work together with its Optical Interposer platform, making AI, data centers, and quantum computing faster and more efficient. Katie Perry sat down with CRO Raju Kankipati to discuss how POET Technologies is scaling its business, driving innovation in photonics, and powering the future of AI.

Stocktwits

3,041,687 views • 9 months ago

"A Steam Train Coming Down the Tracks," Dr. Angus Dalgleish on COVID Boosters and Cancer IMA Senior Fellow, Oncology Dr. Angus Dalgleish recently sat down with us to discuss what he is seeing with his cancer patients, why he believes COVID boosters are behind the exponential rise in cancer, and why the shots must be halted immediately. Watch the full interview now.
31:02

"A Steam Train Coming Down the Tracks," Dr. Angus Dalgleish on COVID Boosters and Cancer IMA Senior Fellow, Oncology Dr. Angus Dalgleish recently sat down with us to discuss what he is seeing with his cancer patients, why he believes COVID boosters are behind the exponential rise in cancer, and why the shots must be halted immediately. Watch the full interview now.

Independent Medical Alliance

25,936 views • 2 months ago

Galaxy Digital $GLXY launched GalaxyOne, a new platform precision-built for modern investors. It combines institutional strength with high-yield cash products, crypto trading, and equities investing in one comprehensive ecosystem. Katie Perry sat down with Managing Director & Head of GalaxyOne, Zac Prince, to discuss how Galaxy is extending its multi-asset offerings to retail investors, the platform's strategy and roadmap, and the long-term vision of GalaxyOne.
14:32

Galaxy Digital $GLXY launched GalaxyOne, a new platform precision-built for modern investors. It combines institutional strength with high-yield cash products, crypto trading, and equities investing in one comprehensive ecosystem. Katie Perry sat down with Managing Director & Head of GalaxyOne, Zac Prince, to discuss how Galaxy is extending its multi-asset offerings to retail investors, the platform's strategy and roadmap, and the long-term vision of GalaxyOne.

Stocktwits

1,393,823 views • 8 months ago

Ondo is bringing Wall Street to the world. At Stocktoberfest, Katie Wheeler, Head of Partnerships at Ondo Finance, sat down with Katie Perry to discuss how tokenization is transforming traditional finance. The goal: expand global access to U.S. stocks, ETFs, and Treasuries, especially in places where traditional brokerage access is limited.
9:13

Ondo is bringing Wall Street to the world. At Stocktoberfest, Katie Wheeler, Head of Partnerships at Ondo Finance, sat down with Katie Perry to discuss how tokenization is transforming traditional finance. The goal: expand global access to U.S. stocks, ETFs, and Treasuries, especially in places where traditional brokerage access is limited.

Stocktwits

26,705 views • 9 months ago

mRNA Biotechnology is Fundamentally Flawed It is dangerous because the pharmacokinetics remain unknown including the routes and rates of elimination. The protein assembled from mRNA cannot be controlled for onset/offset, dose, and duration. For cancer patients mRNA toxicity will be difficult to detect because they are sick with cancer, and thus mRNA could do more damage and remain undetected by drug safety systems. Like nuclear technology, mRNA needs strict and special regulatory control. Alex Jones
1:08

mRNA Biotechnology is Fundamentally Flawed It is dangerous because the pharmacokinetics remain unknown including the routes and rates of elimination. The protein assembled from mRNA cannot be controlled for onset/offset, dose, and duration. For cancer patients mRNA toxicity will be difficult to detect because they are sick with cancer, and thus mRNA could do more damage and remain undetected by drug safety systems. Like nuclear technology, mRNA needs strict and special regulatory control. Alex Jones

Peter A. McCullough, MD, MPH®

130,328 views • 1 year ago

Archer Aviation is pioneering electric air taxis that can turn a 90 minute airport commute into a quiet 10 minute battery powered flight. Their work spans urban mobility, FAA certification progress, and emerging defense applications. Katie Perry sat down with Archer Founder and CEO Adam Goldstein to break down how electric air taxis (EVTOLs) are about to transform transportation, from civilian urban mobility to the future of U.S. defense aviation.
22:27

Archer Aviation is pioneering electric air taxis that can turn a 90 minute airport commute into a quiet 10 minute battery powered flight. Their work spans urban mobility, FAA certification progress, and emerging defense applications. Katie Perry sat down with Archer Founder and CEO Adam Goldstein to break down how electric air taxis (EVTOLs) are about to transform transportation, from civilian urban mobility to the future of U.S. defense aviation.

Stocktwits

22,291 views • 8 months ago

$20B Skin Cancer Market Demands Non-Invasive Solutions – Medicus Delivers | Airing on CNBC and FOX Business What if treating skin cancer didn’t require painful, invasive surgeries? Medicus Pharma Ltd is revolutionizing cancer care with its non-invasive, targeted chemotherapy—delivering treatment directly to tumor sites with minimal discomfort. 🔬 Advancing through Phase 2 clinical studies 📈 Skin cancer treatment market projected to exceed $20B by 2030 💡 A cost-effective, surgery-free solution Medicus Pharma is at the forefront of a new era in oncology, prioritizing patient comfort and treatment efficacy. Learn more about this game-changing innovation: (NASDAQ: $MDCX) #MedicusPharma #SkinCancerTreatment #BiotechInvesting #Biotech #CancerTreatment #SkinCancer #StocksinNews #StockstoBuy
0:30

$20B Skin Cancer Market Demands Non-Invasive Solutions – Medicus Delivers | Airing on CNBC and FOX Business What if treating skin cancer didn’t require painful, invasive surgeries? Medicus Pharma Ltd is revolutionizing cancer care with its non-invasive, targeted chemotherapy—delivering treatment directly to tumor sites with minimal discomfort. 🔬 Advancing through Phase 2 clinical studies 📈 Skin cancer treatment market projected to exceed $20B by 2030 💡 A cost-effective, surgery-free solution Medicus Pharma is at the forefront of a new era in oncology, prioritizing patient comfort and treatment efficacy. Learn more about this game-changing innovation: (NASDAQ: $MDCX) #MedicusPharma #SkinCancerTreatment #BiotechInvesting #Biotech #CancerTreatment #SkinCancer #StocksinNews #StockstoBuy

BTV & CEO Clips

18,775 views • 1 year ago

🚨 Quantum stocks are having a moment on Stocktwits so we went straight to the source: Katie Perry x CEO Alan Baratz of D-Wave ($QBTS) sat down for a 1:1 exclusive to discuss 💡 Quantum breakthroughs 🔗 AI integration 🚀 What’s next for $QBTS Catch the full interview👇
20:41

🚨 Quantum stocks are having a moment on Stocktwits so we went straight to the source: Katie Perry x CEO Alan Baratz of D-Wave ($QBTS) sat down for a 1:1 exclusive to discuss 💡 Quantum breakthroughs 🔗 AI integration 🚀 What’s next for $QBTS Catch the full interview👇

Stocktwits

4,181,760 views • 1 year ago

CANCER IS REAL BUSINESS Dr. Stanislaw Burzynski's unconventional cancer treatment has sparked intense debate. His Antineoplaston therapy has inspired hope in some, but the medical mainstream remains skeptical. Devotees see him as a visionary, while detractors dismiss him as a quack. The controversy raises important questions about the future of cancer treatment. Can conventional and alternative approaches find common ground? How can we balance innovation with rigor and oversight? The answers will have far-reaching implications for patients and the medical community. The debate around Dr. Stanislaw Burzynski's cancer treatment is complicated by the FDA's involvement. Critics argue that the agency's oversight has hindered Burzynski's efforts, citing instances of bureaucratic delays and stringent regulations that can slow down the approval process for new treatments. Some claim the FDA's stance is influenced by a preference for conventional therapies and pressure from the pharmaceutical industry, suggesting the agency's actions are more about protecting established interests than safeguarding patients. However, others believe the FDA is fulfilling its role of ensuring treatments meet high safety and efficacy standards. They assert that Burzynski's methods have yet to be convincingly validated and express concerns about potential risks associated with his treatment. The reality may be somewhere in the middle. While the FDA aims to protect patients, its approach can sometimes be perceived as overly strict. Finding a balance between promoting innovation and maintaining robust oversight is key to offering patients safe, effective cancer treatments while also fostering progress in medical research.
2:50

CANCER IS REAL BUSINESS Dr. Stanislaw Burzynski's unconventional cancer treatment has sparked intense debate. His Antineoplaston therapy has inspired hope in some, but the medical mainstream remains skeptical. Devotees see him as a visionary, while detractors dismiss him as a quack. The controversy raises important questions about the future of cancer treatment. Can conventional and alternative approaches find common ground? How can we balance innovation with rigor and oversight? The answers will have far-reaching implications for patients and the medical community. The debate around Dr. Stanislaw Burzynski's cancer treatment is complicated by the FDA's involvement. Critics argue that the agency's oversight has hindered Burzynski's efforts, citing instances of bureaucratic delays and stringent regulations that can slow down the approval process for new treatments. Some claim the FDA's stance is influenced by a preference for conventional therapies and pressure from the pharmaceutical industry, suggesting the agency's actions are more about protecting established interests than safeguarding patients. However, others believe the FDA is fulfilling its role of ensuring treatments meet high safety and efficacy standards. They assert that Burzynski's methods have yet to be convincingly validated and express concerns about potential risks associated with his treatment. The reality may be somewhere in the middle. While the FDA aims to protect patients, its approach can sometimes be perceived as overly strict. Finding a balance between promoting innovation and maintaining robust oversight is key to offering patients safe, effective cancer treatments while also fostering progress in medical research.

Teaᡣ𐭩

125,284 views • 2 years ago

Trillions are set to be tokenized via Ondo Finance. Ondo’s Ian De Bode (Ian De Bode) joins Katie Perry to explore the $100 trillion opportunity for tokenized stocks, ETFs, and Treasuries. "Ondo is leading the shift to onchain finance, tokenizing traditional assets like Treasuries, stocks, and ETFs to make them globally accessible, transferable 24/7, and easier to move across platforms and markets.” They discuss: - How tokenization is going mainstream - Why stablecoins are just the beginning - The reasons major institutions are working with Ondo Watch to see why the future of finance is being built onchain.
19:34

Trillions are set to be tokenized via Ondo Finance. Ondo’s Ian De Bode (Ian De Bode) joins Katie Perry to explore the $100 trillion opportunity for tokenized stocks, ETFs, and Treasuries. "Ondo is leading the shift to onchain finance, tokenizing traditional assets like Treasuries, stocks, and ETFs to make them globally accessible, transferable 24/7, and easier to move across platforms and markets.” They discuss: - How tokenization is going mainstream - Why stablecoins are just the beginning - The reasons major institutions are working with Ondo Watch to see why the future of finance is being built onchain.

Stocktwits

4,106,340 views • 9 months ago

Kicked off the #HillNationSummit with a great conversation with Leland Vittert about how FDA is addressing today's public health challenges. Whether it's accelerating access to cures, meaningful treatments and diagnostics, or making food healthier for children, we're focused on the priorities that matter most to American families.
1:49

Kicked off the #HillNationSummit with a great conversation with Leland Vittert about how FDA is addressing today's public health challenges. Whether it's accelerating access to cures, meaningful treatments and diagnostics, or making food healthier for children, we're focused on the priorities that matter most to American families.

Dr. Marty Makary

54,705 views • 1 year ago

Big news: Private market data is officially live on Stocktwits! In partnership with Nasdaq Private Market, we’re bringing you institutional-grade pricing, valuations and funding insights. Plus, Polymarket prediction markets for top private companies.
0:36

Big news: Private market data is officially live on Stocktwits! In partnership with Nasdaq Private Market, we’re bringing you institutional-grade pricing, valuations and funding insights. Plus, Polymarket prediction markets for top private companies.

Stocktwits

33,695 views • 2 months ago